ABT
Abbott Laboratories
Abbott Laboratories historical holders
total: 11
Vulcan Value Partners Abbott Laboratories transactions over time
- Total transactions:
- 12
- New positions:
- 2
- Sold out:
- 2
- Added:
- 1
- Reduced:
- 7
- Held since:
- 2022 Q4
- Held for:
- 9 quarters
- Latest activity:
- 2025 Q1
Vulcan Value Partners has been an institutional investor in Abbott Laboratories (ABT) since 2014 Q2. According to 2026 Q1 report, Vulcan Value Partners doesn't hold any shares. The fund/company first acquired ABT in 2014 Q2, initially purchasing 785 shares. Vulcan Value Partners later completely sold out the position and reinvested in ABT again in 2022 Q4. Since the initial investment, Vulcan Value Partners has made 11 more transactions in this position.
When did Vulcan Value Partners exit their ABT position?
Vulcan Value Partners no longer holds Abbott Laboratories (ABT). They sold off their entire position in 2025 Q1, closing out an investment that began in 2014 Q2.
When did Vulcan Value Partners first invest in ABT?
Vulcan Value Partners first invested in Abbott Laboratories (ABT) in 2014 Q2 at the reported quarter-end price of $40.76 per share, acquiring 785 shares in their initial purchase.
What is Vulcan Value Partners's average cost basis for ABT?
Based on historical transaction data, Vulcan Value Partners's estimated cost basis for Abbott Laboratories (ABT) is approximately $109.70 per share. This represents their average reported price* across all buy transactions.
Has Vulcan Value Partners reinvested in ABT after selling?
Yes, Vulcan Value Partners has shown renewed interest in Abbott Laboratories (ABT). After completely selling their position, they reinitiated an investment in 2022 Q4, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $109.70
- Weighted AVG sell price:
- $110.01
ABT transactions history by Vulcan Value Partners
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q1
|
0.00%
|
0
|
$113.14
|
|
-100% (-370,518)
|
-0.7%
|
|
2024 Q4
|
0.70%
|
370,518
|
$113.14
|
$41,919,956
|
-4.54% (-17,604)
|
-0.03%
|
|
2024 Q3
|
0.74%
|
388,122
|
$114.01
|
$44,249,789
|
-22.45% (-112,347)
|
-0.19%
|
|
2024 Q2
|
0.79%
|
500,469
|
$103.86
|
$51,978,000
|
-11.93% (-67,791)
|
-0.1%
|
|
2024 Q1
|
0.94%
|
568,260
|
$113.56
|
$64,530,000
|
-14.56% (-96,828)
|
-0.16%
|
|
2023 Q4
|
1.07%
|
665,088
|
$110.06
|
$73,198,000
|
-8.41% (-61,077)
|
-0.1%
|
|
2023 Q3
|
1.07%
|
726,165
|
$96.79
|
$70,283,000
|
-13.65% (-114,821)
|
-0.14%
|
|
2023 Q2
|
1.15%
|
840,986
|
$108.92
|
$91,602,000
|
-7.21% (-65,321)
|
-0.09%
|
|
2023 Q1
|
1.16%
|
906,307
|
$101.28
|
$91,793,000
|
+0.94% (+8,444)
|
+0.01%
|
|
2022 Q4
|
1.32%
|
897,863
|
$109.78
|
$98,563,000
|
new
|
+1.32%
|
|
2014 Q3
|
0.00%
|
$40.76
|
-100% (-785)
|
|||
|
2014 Q2
|
0.00%
|
$40.76
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.